AQB

AquaBounty Technologies, Inc. operates as a land-based aquaculture company focused on producing genetically engineered Atlantic salmon. Headquartered in Maynard, Massachusetts, the company commercializes its AquAdvantage Salmon, which represents the first genetically modified animal approved for human consumption by the U.S. Food and Drug Administration. The company's salmon is engineered to grow faster than conventional Atlantic salmon, reaching market size in approximately 18 months compared to 30 months for traditional farmed salmon. AquaBounty operates indoor Recirculating Aquaculture Systems (RAS) facilities in Albany, Indiana and Rollo Bay, Prince Edward Island, Canada, which enable year-round production with reduced environmental impact compared to traditional ocean-pen farming. The Indiana facility spans approximately 120,000 square feet with a production capacity of 1,200 metric tons annually, while the Canadian farm produces approximately 250 metric tons per year. The company sells its products primarily to foodservice distributors and retail customers in the United States and Canada. AquaBounty's business model emphasizes biosecurity, sustainability, and controlled farming conditions that eliminate ocean pollution and reduce disease transmission risks. The company continues to work toward expanding production capacity and achieving commercial-scale profitability while navigating regulatory frameworks across different jurisdictions for its bioengineered salmon products.